EGFR and non-small cell lung carcinoma: A meta-analysis of 456 studies showed that EGFR variants have a prevalence of 17.4% [95% confidence interval (CI): 15.8–18.9] and 38.8% (95% CI: 36.8–40.8) in Caucasian and Asian patients with NSCLC, respectively [5].